CYC1

Cytochrome c1, heme protein, mitochondrial · P08574 · CYC1 on Sugi Atlas →

1,769 patent compounds predicted against CYC1, 1,485 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gilteritinib (SCHEMBL282229)	1.00	1/20
SCHEMBL328303	0.94	1/20
Gilteritinib (SCHEMBL21819929)	0.92	1/20
Gilteritinib (SCHEMBL22684910)	0.91	1/20
Gilteritinib (SCHEMBL22684912)	0.91	1/20
SCHEMBL21455071	0.89	1/20
SCHEMBL22652336	0.89	1/20
SCHEMBL10156928	0.89	1/20
Gilteritinib (SCHEMBL22684909)	0.88	1/20
Gilteritinib (SCHEMBL22684903)	0.87	1/20
SCHEMBL22694087	0.87	1/20
SCHEMBL21426963	0.86	1/20
SCHEMBL21427160	0.86	1/20
Gilteritinib (SCHEMBL23149445)	0.86	1/20
SCHEMBL25483843	0.86	1/20
SCHEMBL25483845	0.86	1/20
SCHEMBL282490	0.85	1/20
SCHEMBL282491	0.85	1/20
Gilteritinib (SCHEMBL22684907)	0.85	1/20
SCHEMBL22694094	0.85	1/20

Clinical trials — most relevant to CYC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?	PHASE1/PHASE2	COMPLETED
Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension	PHASE1/PHASE2	WITHDRAWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
In Vivo Assessment of Cellular Metabolism in Humans	PHASE1	COMPLETED
Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?	PHASE1	UNKNOWN
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome	nan	COMPLETED
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Reactive Oxygen Species Following Aortic Valve Replacement	nan	COMPLETED
Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure	nan	RECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19	nan	WITHDRAWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Leg Ulcers Standards of Care Enhancement	nan	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Effect of Diaphragm Stimulation During Surgery	nan	COMPLETED
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Effects of Chronic Dietary Exposure to Branched Chain Amino Acids	nan	COMPLETED
Biological Response to Brief Psychological Challenge	nan	COMPLETED
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis	nan	UNKNOWN
Human Adaptation to High Altitude	nan	UNKNOWN
Parkinson's Diseases Susceptibility Genes and Pesticides	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYC1 binder may also engage these)

Protein	Name	Similarity
P00125	—	0.999	P00125 →
Q9D0M3	—	0.998	Q9D0M3 →
P07143	—	0.976	P07143 →
A0A1D8PHA3	—	0.975	A0A1D8PHA3 →
P07142	—	0.974	P07142 →
Q00988	—	0.972	Q00988 →
O59680	—	0.971	O59680 →
Q9FKS5	—	0.969	Q9FKS5 →
Q66LN0	—	0.969	Q66LN0 →
PTGES2	Prostaglandin E synthase 2	0.967	landscape →
Q60HD0	—	0.967	Q60HD0 →
P51687	—	0.966	P51687 →
Q9N0A4	—	0.965	Q9N0A4 →
Q91YH5	—	0.965	Q91YH5 →
Q8R086	—	0.965	Q8R086 →
Q28CM7	—	0.964	Q28CM7 →
Q1LVN8	—	0.964	Q1LVN8 →
Q3B8B2	—	0.964	Q3B8B2 →
Q54D07	—	0.964	Q54D07 →
Q8CIG8	—	0.964	Q8CIG8 →
Q8IYB8	—	0.964	Q8IYB8 →
Q5RJV0	—	0.964	Q5RJV0 →
Q80YD1	—	0.963	Q80YD1 →
Q60HE5	—	0.963	Q60HE5 →
PRMT5	Protein arginine N-methyltransferase 5	0.963	landscape →
Q6NUA1	—	0.963	Q6NUA1 →
Q9WU20	—	0.963	Q9WU20 →
A9JS49	—	0.963	A9JS49 →
Q8CGK3	—	0.963	Q8CGK3 →
Q5R698	—	0.962	Q5R698 →